Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-23R drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-23R ECD-Fc Fusion Protein / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed (native glycosylation). |
View IL23R Products |
| Gene Delivery | IL-23R Lentivirus Premade Particles Full-length human IL-23R ORF for stable cell line construction. High Titer (>10^8 TU/ml). |
View IL23R Products |
| Benchmark Ab | Anti-IL-23R Neutralizing / Biosimilar Antibody Recombinant positive control for binding/competition assays and assay standardization. |
View IL23R Products |
| Validator | IL-23R siRNA Set Gene-specific knockdown for target specificity verification and selectivity checks. |
View IL23R Products |
| Related Target A: IL-23A (p19) | IL-23 Heterodimer Protein Specific ligand for IL-23R, crucial for receptor-ligand interaction assays and cell activation controls. |
View IL23A Products |
| Related Target B: IL-12RB1 | IL-12RB1 / IL12RB1 Protein Co-receptor that forms the functional IL-23 receptor complex with IL-23R. Used for heterodimer formation studies. |
View IL12RB1 Products |
| Related Target C: IL-17A | IL-17A Cytokine Downstream pathway marker for functional readout in cell-based assays and combination therapy research. |
View IL17A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Receptor Complex Conformation & Cell-based Signaling (JAK/STAT) | Lentivirus-mediated stable cell line generation preserves native membrane structure; full-length IL-23R expressed in HEK293 for native conformation and STAT3 signaling validation. |
| Cross-species Evaluation (Cyno/Mouse) for Preclinical Translation | Human/Mouse/Cyno ortholog IL-23R ECD proteins available with >95% purity, sequence verified by Mass Spec. |
| IL-12 Selectivity Screening (avoid off-target IL-12 inhibition) | IL-12RB1 homolog panel proteins strictly verified for competitive binding assays to ensure selective IL-23R blockade. |
| Lack of Reliable Controls & Assay Standardization | Clinical benchmark recombinant/biosimilar antibodies included for reliable assay normalization. |
| False Positives in Binding Screens | Validated siRNA available for target-specific knockdown and selectivity checks. |
Live IL-23R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-23 pathway therapeutics is evolving rapidly. While early-generation biologics primarily targeted the IL-23 ligand (p19 or p40 subunits) to treat psoriasis and inflammatory bowel disease (IBD), the strategic focus is now shifting toward targeting the IL-23 Receptor (IL-23R) directly. First-generation anti-IL-23p19 biologics (guselkumab, risankizumab) dominate the psoriasis market, but next-generation programs pursue IL-23R antagonism for distinct pharmacokinetic profiles, including oral bioavailability. Key players include Janssen with JNJ-77242113 (icotrokinra), an oral peptide in Phase III for psoriasis, and Boehringer Ingelheim with BI 655651, an anti-IL-23R mAb in Phase II for Crohn's disease and UC. As oral IL-23R antagonists advance, the competitive landscape bifurcates between high-affinity parenteral mAbs and convenience-driven oral peptides, with combination strategies against IL-17A/F representing the next wave of differentiation. R&D is heavily focused on achieving robust mucosal healing in IBD and overcoming systemic delivery challenges for small molecules.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Oral Peptide Antagonist | Janssen (JNJ-77242113 / Icotrokinra), Protagonist/J&J | Psoriasis, PsA, IBD (Crohn's, UC) | Receptor Binding Kinetics & High-Concentration Stability (Need high-purity ECD-Fc for SPR and stability assays) |
| Anti-IL-23R Monoclonal Antibody | Boehringer Ingelheim (BI 655651), Various Biopharma | Crohn's Disease, UC, Autoimmune Disorders | Heterodimer Validation with IL-12RB1 (Need cross-reactive Abs and lentivirus for STAT3 reporter cells) |
| Small Molecule Inhibitor | Undisclosed Early-stage Biotech | Refractory IBD, Autoimmune | Competitive Binding vs IL-23 & Selectivity (Need mutant vs WT proteins, structural stability) |
| Anti-IL-23p19 (Benchmark) | AbbVie, Eli Lilly, Janssen | Plaque Psoriasis | Comparative Pharmacology (Need IL-23 ligand controls) |
Key Molecular Features of IL-23R
IL-23R (UniProt Q5VWK5) is a type I transmembrane protein containing two Fibronectin type-III domains (Fibronectin type-III 1 and Fibronectin type-III 2) in its extracellular region, which are critical for ligand binding and receptor dimerization with IL-12RB1. Key genetic variants include missense mutations: rs1884444, rs11465797, and rs7530511, which have been associated with autoimmune disease susceptibility and may impact drug binding or response. Understanding these structural features and mutations is essential for designing selective antagonists and monitoring potential resistance.
Molecular Differentiation & Assay Strategy
For Best-in-Class IL-23R drug development, the following technical requirements must be addressed:
- Affinity & Binding Kinetics: Antibodies need sub-nanomolar affinity; oral peptides require picomolar affinity to compensate for shorter half-life. TarMart provides high-purity human/monkey/mouse IL-23R ECD proteins for SPR/BLI cross-species kinetic analysis.
- IL-12 Selectivity: Molecules must bind unique epitopes on IL-23R (D1-D2 domains) without cross-reacting with IL-12RB1 to preserve Th1 anti-viral responses. TarMart offers IL-12RB1 homolog panels for competitive binding and heterodimer disruption assays.
- Oral Peptide Stability: Peptide antagonists must survive gastrointestinal pH (1-8) and proteases. TarMart's HEK293-expressed IL-23R ECD enables DMSO/pH stability screening; Caco-2 cell lines with IL-23R lentivirus allow permeability and binding validation.
- Signaling Pathway Integrity: Blockade of IL-23-induced JAK2/TYK2/STAT3 phosphorylation must be verified. TarMart lentivirus constructs stable reporter cell lines (Ba/F3-IL-23R or HEK293-STAT3-Luc) for functional cell-based assays.
- Resistance Mutation Monitoring: Long-term therapy may select for IL-23R mutations. TarMart offers custom recombinant proteins carrying clinically relevant variants (e.g., rs1884444, rs11465797, rs7530511) for early resistance screening.